Therapy for regionally unresectable pancreatic cancer

Surgical Clinics of North America

Volumn 81, Issue 3, 2001, Pages 691-697

  Kozuch, Peter ^a   Petryk, Magdalena ^a   Evans, Andrew ^b   Bruckner, Howard W ^a,c,d  

^a Division of Medical Oncology   (United States)

^b Radiation Oncology ^*

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d New York Pancreatic Biliary Study Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR;

BEAM THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; HUMAN; INTERSTITIAL RADIATION; METASTASIS; MULTIMODALITY CANCER THERAPY; ONCOGENE K RAS; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL;

EID: 0034972566     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(05)70154-7     Document Type: Conference Paper

References (25)

1. Regional vs systemic chemotherapy for advanced pancreatic cancer: A randomized study
2. Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: Result of a feasibility study
3. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
4. Phase I trial of concurrent gemcitabine, infusional 5-fluorouracil, and radiation therapy in patients with localized, unresectable pancreatic adenocarcinoma
5. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma
6. Treatment of locally unresectable carcinoma of pancreas: Comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone
7. Radical reoperation for advanced pancreatic carcinoma
8. Combined modality therapy for stage II and III pancreatic carcinoma
9. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil
10. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers
11. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin
12. Palliative and adjuvant regional chemotherapy in pancreatic cancer
13. A phase I trial of radiation dose escalation with full dose gemcitabine in patients with pancreatic cancer
14. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer
15. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil
16. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas
17. Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas
18. Surgical complications of intraoperative radiation therapy: The Radiation Therapy Oncology Group experience
19. External beam vs intraoperative and external beam irradiation for locally advanced pancreatic cancer
20. Phase I trial of gemcitabine, cisplatin and external beam radiation therapy for pancreatic cancer
21. Survival advantage of combined chemoradiotherapy compared with resection as initial treatment for regional pancreatic carcinoma: An outcomes trial
22. Intraoperative radiation therapy of pancreatic carcinoma: A report of RTOG-8505
23. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole
24. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer
25. Radiochemotherapy including gemcitabine and 5-fluorouracil for treatment of locally advanced pancreatic cancer